As part of our series focussing on new medicines available in Australia, we have added a product review of the use of semaglutide in four STEP trials focusing on adults with obesity or overweight.
This review discusses indications and dosage, contraindications and a series of clinical studies featuring semaglutide. It provides commentary from Associate Professor Sarah Glastras, Head of Department and Senior Staff Specialist at the Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital.
Please login below to download this issue (PDF)